Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
September 4, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
Close Move
All Press Releases for September 28, 2007 Subscribe to this News Feed      
 

Investigators to Meet at Summit to Advance Clinical Research for Spinal Muscular Atrophy

With the recent introduction of SMA legislation in both the U.S. House of Representatives and the U.S. Senate to create a national clinical trials network for spinal muscular atrophy (SMA), the leading advocacy organizations are hosting a two-day summit to work toward reducing or eliminating barriers to development of the drugs that would be tested in that network.

Bethesda, MD (PRWEB) September 28, 2007 -- With the recent introduction of SMA legislation in both the U.S. House of Representatives and the U.S. Senate to create a national clinical trials network for spinal muscular atrophy (SMA), the leading advocacy organizations are hosting a two-day summit to work toward reducing or eliminating barriers to development of the drugs that would be tested in that network.

The SMA Summit on Drug Development, which is being held on September 28 and 29 at the Hyatt Regency Bethesda, in Bethesda, MD, will include representatives from the pharmaceutical industry, family support groups, clinicians and government. These stakeholders in the clinical research process will discuss infrastructure, regulatory, and community support needs for evaluating treatments in development. The goal is to speed the development and approval of drugs designed to treat SMA, for which there is currently no approved treatment.

Spinal muscular atrophy is a neuromuscular disease that kills more children under two than any other genetic disorder. It affects the victim's motor neurons, causing muscle atrophy, loss of strength, disability and premature death due to respiratory complications in the majority of affected children.

Both the bill and the drug summit were conceived and implemented through the collaboration of SMA organizations and other parties that have an interest in accelerating a treatment and cure for this disease. These efforts are in anticipation of clinical trials to test new drug treatments for SMA.

Media Contacts:

Lenna Scott
Families of SMA
http://www.fsma.org
(847) 975-4171
lenna(at)fsma.org

Steve Mullen
Fight SMA
http://www.fightsma.org
(804) 382-0017
steve(at)endgamepr.com

Cynthia Joyce
SMA Foundation
http://www.smafoundation.org
(646) 253-7102
cjoyce(at)smafoundation.org

Bob Mackle
MDA
http://www.mdausa.org
(520) 529-5317
bobmackle(at)mdausa.org

###

Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/U3F1YS1GYWx1LUNyYXMtTWFnbi1UaGlyLVplcm8=

Technorati Tags

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web


Other Releases by this Member
OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
BlogThis
ShareIt

Share The News

Submit this press release easily to any of these major bookmarking and social media sites.

CONTACT INFORMATION
Steve Mullen
EndGame Public Relations
804-382-0017
Email us Here
View Our Newsroom
ATTACHED FILES

Fight SMA

Fight SMA

SMA Foundation

SMA Foundation

Families of SMA

Families of SMA

MDA

MDA

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these releases. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright